CTKBCytek Biosciences, Inc.

$553M

Q3 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$40M+17.7% YoY

Gross Profit

$27M66.4% margin

Operating Income

$1M3.4% margin

Net Income

$2M4.1% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+0.8%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$9M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$499M

Total Liabilities

$83M

Stockholders' Equity

$416M

Cash & Equivalents

$342M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$34M	+17.7%
Gross Profit	$27M	$21M	+26.2%
Operating Income	$1M	$3M	-53.1%
Net Income	$2M	$1M	+17.3%

Revenue Segments

Product

$36M90%

Service

$4M10%

Geographic Segments

UNITED STATES

$23M56%

EMEA

$10M25%

Asia Pacific

$7M18%

Other

$212,0001%

CTKB Q3 2022 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena